Alexion Pexelizumab Failed CABG Trial Could Support Acute MI Claim – Firm
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion’s failed pexelizumab Phase III coronary artery bypass graft surgery trial could serve as a supportive trial for an acute myocardial infarction indication, the firm says.